CSL stock draws buy call as turnaround proof remains ahead

CSL stock received a buy recommendation from Mark Elzayed of Vestra Capital in an investor analysis published by The Motley Fool Australia on Thursday, November 12, 2026. The assessment keeps the focus on whether CSL can turn its recovery in sentiment into more dependable earnings growth.

Elzayed described CSL as an ASX 200 healthcare heavyweight and said the company had faced significant challenges since the Covid period. His recommendation rests on a turnaround that management says is under way, but he stressed that the next phase depends on reliable earnings growth, stronger commercial execution and evidence that restructuring can improve profitability without weakening research capabilities.

Recovery still needs operating proof

CSL management is forecasting underlying profit growth of about 5% in fiscal 2027. That outlook gives investors a measurable test for the recovery plan, particularly as the company works to improve execution across its business and rebuild confidence after a difficult period.

Elzayed characterized the stock as a potential momentum buy rather than a confirmed technical breakout. In his view, the investment case becomes stronger if the recovery can hold and future results show clearer improvement in earnings. The distinction matters for investors: the recommendation supports the turnaround thesis, but it does not remove the need for operating evidence.

CSL stock traded at 125.33 euros on Lang & Schwarz at 09:40 CET on Thursday, November 12, 2026.

Broader Australian healthcare sentiment remains relevant as investors assess whether CSL's recovery can develop into durable earnings momentum. The S&P/ASX 200 provides the wider market context for the stock.

More news and analyses on CSL stock.